Study of Apatinib in Patients With Differentiated Thyroid Cancer
The purpose of this study is to assess the efficacy and safety of apatinib in locally advanced/metastatic radioactive iodine-refractory/resistant differentiated thyroid cancer
Thyroid Cancer
DRUG: Apatinib|DRUG: Apatinib
Disease control rate (DCR), Disease control rate, An expected average of 8 weeks|Objective response rate (ORR), Objective response rate, An expected average of 8 weeks
Progression free survival (PFS), progression free survival, Up to approximately 43 months|Overall survival (OS), overall survival, Up to approximately 48 months
The purpose of this study is to assess the efficacy and safety of apatinib in locally advanced/metastatic radioactive iodine-refractory/resistant differentiated thyroid cancer